Vistagen Therapeutics (VTGN) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Vistagen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings data on Monday. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.13), MarketWatch Earnings reports.

Vistagen Therapeutics stock opened at $2.07 on Tuesday. Vistagen Therapeutics has a 52 week low of $0.69 and a 52 week high of $2.65. The company has a market capitalization of $54.73 million, a P/E ratio of -1.87 and a beta of 0.45.

Several research firms have recently weighed in on VTGN. Oppenheimer set a $6.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Maxim Group set a $6.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 5th. Finally, Zacks Investment Research upgraded Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Thursday, August 30th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $8.30.



About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: Investing in Growth Stocks

Earnings History for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply